Skip to main content
. 2020 Oct 5;124(2):383–390. doi: 10.1038/s41416-020-01099-7

Fig. 4. PFS for individual patients in the dose-expansion phase (tumour response analysis set).

Fig. 4

Baseline PD-L1 TC ≥20% was indicative of high PD-L1 expression. AE adverse event, EGFR epidermal growth factor receptor, H high (PD-L1 TC ≥20%), L low/negative (PD-L1 TC <20%), NE not evaluable (no sample or <100 TCs), PD-L1 programmed cell death ligand-1, PFS progression-free survival, TC tumour cell.